Saladax Biomedical Inc (Saladax) is a medical equipment company that develops diagnostic tests. The company develops, manufactures, and markets assays that provide rapid therapeutic drug levels for essential and life-saving medicines prescribed by psychiatrists and oncologists. It provides products such as My5-FU, MyPaclitaxel, MyImatinib and MyDocetaxel, among others. Its My5-FU measures and helps physicians to optimize a patient’s exposure to 5-fluorouracil. The company’s products are used in the treatment of cell lung cancer, digestive tract, prostate, and head and neck cancers. It markets its products in the US and abroad. Saladax is headquartered in Bethlehem, Pennsylvania, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Saladax Biomedical Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Saladax Biomedical Inc Company Overview
Saladax Biomedical Inc Company Snapshot
Saladax Biomedical Inc Pipeline Products and Ongoing Clinical Trials Overview
Saladax Biomedical Inc - Locations And Subsidiaries
Head Office
Recent Developments
Saladax Biomedical Inc, Recent Developments
Mar 15, 2022: Beckman Coulter introduces antipsychotic drug testing to address unmet clinical need for more than 69 million people living with serious mental conditions
Feb 16, 2021: Saladax Biomedical announces Health Canada approval of five MyCare psychiatry laboratory diagnostic assay
Dec 16, 2020: HLS Therapeutics announces update on Health Canada filings for MyCare
Jul 08, 2020: Saladax Biomedical launches clozapine test in the US after FDA grants market authorization
Jun 01, 2020: HLS Therapeutics to become distributor of the Saladax MyCare psychiatry line including the Insite point-of-care device and antipsychotic reagents
Oct 24, 2019: Studies feature clinical validations of Clozapine point of care testing using a single drop of blood to aid psychiatrists in better treatment of patients with Schizophrenia
Jul 25, 2018: Saladax Biomedical launches game-changing assays for psychotherapeutics at AACC 2018
Jul 17, 2018: Saladax Submits for FDA Review a Rapid Blood Test for Levels of Risperidone
Mar 21, 2018: Saladax Receives Approval to Sell a New Line of Psychiatry Tests on the European Market
Dec 01, 2014: Saladax Biomedical Announces U.S. Launch of MyImatinib Chemotherapy Exposure Optimization Test